在人类中,慢性mu-opioid受体刺激会降低肌肉交感神经活动
P Kienbaum1, T Heuter, M C Michel
1Abteilung für Anästhesiologie und Intensivmedizin, Biochemisches Forschungslabor, and Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Essen, Germany. peter.kienbaum@uni-essen.de
Circulation
|February 15, 2001
概括
在阿片类药物成患者中,慢性甲使用显著降低了肌肉交感神经活动 (MSA). 这种对交感神经系统活动的减少是通过mu-opioid受体阻塞逆转的.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 心血管生理学心血管生理学
背景情况:
- 阿片类药物成治疗涉及排毒,提供对慢性阿片类药物影响的见解.
- 同情神经系统对慢性阿片类受体刺激的反应尚未完全理解.
研究的目的:
- 测试慢性口服甲是否会降低静止肌肉交感神经活动 (MSA).
- 为了确定m-opioid受体阻断是否在麻醉下排毒期间逆转这种效应.
主要方法:
- 在接受美沙治疗的15名阿片类药物成患者中评估了腹膜MSA和甲醇胺水平.
- 与健康对照对比MSA和甲基荷兰胺.
- 在普罗波麻醉期间评估纳洛 (mu-opioid对抗剂) 的作用.
主要成果:
- 与对照组相比,在接受甲治疗的患者中,休息时的MSA和北上腺素水平显著较低.
- 用纳洛阻塞片受体显著增加了MSA,北上腺素,上腺素,血压和心率.
结论:
- 通过甲的慢性片受体刺激会降低人类的休息MSA.
- 这表明甲调节了交感神经系统的活动.
相关概念视频
Cholinergic Receptors: Muscarinic
4.9K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
4.9K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.3K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.6K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.3K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.3K
Opioid Receptors: Overview
7.4K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.4K
Analgesia and Pain Management
3.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.4K


